Madhu Kumar
Stock Analyst at Goldman Sachs
(3.58)
# 885
Out of 4,761 analysts
153
Total ratings
55.45%
Success rate
19.08%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $136.01 | +24.26% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $3.85 | +55.84% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $19.29 | +34.78% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $14.10 | +20.57% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.87 | +113.90% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $187.86 | -17.49% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $50.26 | +5.45% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $4.91 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $19.90 | +266.83% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $27.52 | +412.35% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $16.38 | +107.57% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $5.78 | +3.81% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $17.77 | -21.22% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $13.33 | +57.54% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $27.07 | -81.53% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.92 | +316.67% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $17.77 | +400.84% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.52 | +1,043.29% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.53 | +1,786.79% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $12.17 | +598.44% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.53 | +2,449.02% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $12.84 | +343.93% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.42 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $2.62 | +34,251.15% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $9.57 | +108.99% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.97 | +10,209.28% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $37.70 | -7.16% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.48 | +12,394.79% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $6.15 | +550.41% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $12.35 | +3,980.97% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $250.59 | -8.22% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $1.31 | +4,480.15% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.83 | +2,085.79% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $30.88 | -30.38% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $47.91 | -50.95% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $136.01
Upside: +24.26%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $3.85
Upside: +55.84%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $19.29
Upside: +34.78%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $14.10
Upside: +20.57%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.87
Upside: +113.90%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $187.86
Upside: -17.49%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $50.26
Upside: +5.45%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.91
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $19.90
Upside: +266.83%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $27.52
Upside: +412.35%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $16.38
Upside: +107.57%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $5.78
Upside: +3.81%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $17.77
Upside: -21.22%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $13.33
Upside: +57.54%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $27.07
Upside: -81.53%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.92
Upside: +316.67%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $17.77
Upside: +400.84%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.52
Upside: +1,043.29%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.53
Upside: +1,786.79%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $12.17
Upside: +598.44%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.53
Upside: +2,449.02%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $12.84
Upside: +343.93%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.42
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $2.62
Upside: +34,251.15%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $9.57
Upside: +108.99%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.97
Upside: +10,209.28%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $37.70
Upside: -7.16%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.48
Upside: +12,394.79%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $6.15
Upside: +550.41%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $12.35
Upside: +3,980.97%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $250.59
Upside: -8.22%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $1.31
Upside: +4,480.15%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.83
Upside: +2,085.79%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $30.88
Upside: -30.38%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $47.91
Upside: -50.95%